



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/549,685	09/19/2005	Eva Caroff	66535.000004	7434
21967	7590	02/17/2010	EXAMINER	
HUNTON & WILLIAMS LLP			PIHONAK, SARAH	
INTELLECTUAL PROPERTY DEPARTMENT				
1900 K STREET, N.W.			ART UNIT	PAPER NUMBER
SUITE 1200				1627
WASHINGTON, DC 20006-1109				
			MAIL DATE	DELIVERY MODE
			02/17/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/549,685	CAROFF ET AL.	

Examiner	Art Unit	
SARAH PIHONAK	1627	

All Participants:

(1) SARAH PIHONAK.

Status of Application: Allowed

(3) ____.

(2) JEFF VOCKRODT.

(4) ____.

Date of Interview: 4 February 2010

Time: _____

Type of Interview:

- Telephonic
 Video Conference
 Personal (Copy given to: Applicant Applicant's representative)

Exhibit Shown or Demonstrated: Yes No

If Yes, provide a brief description: .

Part I.

Rejection(s) discussed:

NONE

Claims discussed:

11-16, 22-33

Prior art documents discussed:

NONE

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

SEE CONTINUATION

Part III.

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Applicant/Applicant's Representative Signature – if appropriate)

Applicant's attorney, Jeff Vockrodt, was contacted regarding the Rule 1.312 amendment submitted on 1/8/2010. It was requested that a supplemental amendment be submitted, regarding claim 32, with the removal of the terms: "or a pharmaceutically acceptable salt thereof". On 2/4/2010, a supplemental amendment was submitted with the proposed change. Claims 11-16 and 22-33 are allowed.